Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eflapegrastim in Pediatric Patients With Solid Tumors or Lymphomas
NCT04570423Phase 2Recruiting
- Sponsor
- Spectrum Pharmaceuticals, Inc.
- Start
- May 2021
- Primary completion
- Oct 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of esketamine in neutropenia, sponsored by Spectrum Pharmaceuticals, Inc.. Started May 2021; status: recruiting.
02
Drugs
esketamine
03
Conditions
neutropenia
Beyond the preview
Go deeper on NCT04570423.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04570423.